Chemistry:TC OT 39
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | "Compound 39";[1] SynOTA[2] |
| Drug class | Oxytocin receptor agonist; Vasopressin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C32H40N8O2S |
| Molar mass | 600.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TC OT 39, also known as "compound 39", is a non-peptide partial agonist of the oxytocin and vasopressin V2 receptors (Ki = 147 nM and >1,000 nM, respectively) and antagonist of the vasopressin V1A receptor (Ki = 330 nM).[3][1] The EC50 values of the drug were 33 nM at the oxytocin receptor and 850 nM at the vasopressin V2 receptor.[1] TC OT 39 was first described in the scientific literature by Gary R. W. Pitt and colleagues in 2004.[3][1] The drug was the first small-molecule oxytocin receptor agonist to be described, though it was the lead optimized compound of a described series of compounds.[3][1] Subsequently, improved analogues like WAY-267,464 (2010), LIT-001 (2018), and LIT-002 (2026) were described.[3][4][5][6]
See also
- Oxytocin receptor agonist
- WAY-267,464
- LIT-001
- LIT-002
- KNX-100
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Non-peptide oxytocin agonists". Bioorganic & Medicinal Chemistry Letters 14 (17): 4585–4589. September 2004. doi:10.1016/j.bmcl.2004.04.107. PMID 15357997.
- ↑ Pederson, Cort (30 November 2015). "Preclinical Testing of Novel Oxytocin Receptor Activators in Models of Autism Phenotypes". https://apps.dtic.mil/sti/html/tr/AD1001175/.
- ↑ 3.0 3.1 3.2 3.3 "The Current Status of Drug Discovery for the Oxytocin Receptor". Methods Mol Biol 2384: 153–174. 2022. doi:10.1007/978-1-0716-1759-5_10. PMID 34550574.
- ↑ "Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist". Neuropharmacology 58 (1): 69–77. January 2010. doi:10.1016/j.neuropharm.2009.07.016. PMID 19615387.
- ↑ "LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism". J Med Chem 61 (19): 8670–8692. October 2018. doi:10.1021/acs.jmedchem.8b00697. PMID 30199637.
- ↑ "LIT-002, a highly potent and selective nonpeptide oxytocin receptor agonist that improves social interaction in mouse models of autism". SSRN Electronic Journal. April 2026. doi:10.2139/ssrn.6624262.
 |  |
